MRNA (modernatx.com) Bathi resik saben saham (EPS TTM)

Moderna, Inc. (MRNA) growth is based on its independence from economic cycles and the success of clinical trials. The 12-month rolling earnings per share history visualizes this trend, where the value -7.11 represents the latest figure. Patented mRNA technologies for combating cancer and large-scale alliances with government institutions worldwide serve as the foundation.

MRNA (Moderna Therapeutics) riwayat Bathi resik saben siji saham sajrone rolas wulan pungkasan saka 04.07.2022 nganti 14.11.2026

Moderna Inc (MRNA) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Moderna, Inc.|MRNA - Prakiraan gabungan firma investasi

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Moderna, Inc.|MRNA - Nilai Wutuh Bisnis

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Moderna|MRNA - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku modernatx.com|MRNA - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- indikator pendapatan resik lan kelipatan nilai:

MRNA - Asil keuangan resik|Bathi sing dikarepake Moderna, Inc.|MRNA - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Moderna|MRNA - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Moderna, Inc.|MRNA - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Moderna|MRNA - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan modernatx.com|MRNA - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Moderna, Inc.

- data pendapatan lan penerimaan dodolan:

MRNA - Volume dodolan perusahaan|Prakiraan volume dodolan Moderna, Inc.|MRNA - Multiplikator P/S|Multiplikator forward rega marang pendapatan Moderna, Inc.

Analisis fundamental perusahaan:MRNA - Moderna, Inc.

Net income per share over 12 months measures the portion of equity attributable to a single security, allowing for an assessment of real business profitability without accounting for share dilution. By analyzing the 12-month net income per share snapshot, an investor determines the capital stability of Moderna, Inc. (MRNA), where the technological superiority of the mRNA platform offsets the decline in demand for legacy products, maintaining margins during the portfolio transformation.

Pesaing utama

SMMT - Bathi saben saham sajrone rolas wulan pungkasan|PCVX (vaxcyte.com) - Bathi saben saham sajrone 12 wulan pungkasan|TARS: Bathi resik saben saham (EPS TTM)|Bathi saben siji saham sajrone 12 wulan pungkasan CRMD (CorMedix Inc)|MCRB (Seres) - Bathi resik saben saham (EPS TTM)|Bathi resik saben siji saham sajrone rolas wulan pungkasan Spero Pharma SPRO|Bathi resik saben saham (EPS TTM) SCYX|Bathi resik saben saham sajrone 12 wulan pungkasan an2therapeutics.com ANTX|PolyPid - Bathi resik saben saham sajrone 12 wulan pungkasan|Bathi saben saham sajrone patang kuartal pungkasan LSB (LakeShore Biopharma Co., Ltd.)|Iterum Therapeutics, plc - Bathi resik saben saham (EPS TTM)|Bathi resik saben saham sajrone patang kuartal pungkasan BiomX Inc. PHGE|soligenix.com (SNGX) - Bathi saben saham sajrone rolas wulan pungkasan|Bathi resik saben siji saham sajrone rolas wulan pungkasan 60 Degrees Pharmaceuticals, Inc. (SXTP)|Bathi saben saham sajrone rolas wulan pungkasan Oragenics|Bathi saben saham sajrone 12 wulan pungkasan OPGN (OpGen Inc)